The therapeutic potential of galectin-1 and galectin-3 in the treatment of neurodegenerative diseases

References

• Dorothée G. Neuroinflammation in neurodegeneration: role in pathophysiology, therapeutic opportunities and clinical perspectives. J Neural Transm. 2018;125:749–750.
   PubMed Web of Science ®Google Scholar
• Chen WW, Zhang X, Huang WJ. Role of neuroinflammation in neurodegenerative disease. Mol Med Rep. 2016;13:3391–3396.
   PubMed Web of Science ®Google Scholar
• Amor S, Puentes F, Baker D, et al. Inflammation in neurodegenerative diseases. Immunology. 2010;129:154–169.
   PubMed Web of Science ®Google Scholar
• Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67(2):181–198.
   PubMed Web of Science ®Google Scholar
• Glass CK, Saijo K, Winner B, et al. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918–934.
   PubMed Web of Science ®Google Scholar
• Espinosa B, Zenteno R, Mena R, et al. O-Glycosylation in sprouting neurons in Alzheimer disease, indicating reactive plasticity. J Neuropathol Exp Neurol. 2001;60(5):441–448.
   PubMed Web of Science ®Google Scholar
• Espinosa B, Guevara J, Hernández P, et al. Characterization of an O-glycosylated plaque-associated protein from Alzheimer disease brain. J Neuropathol Exp Neurol. 2003;62(1):34–41.
   PubMed Web of Science ®Google Scholar
• Limón ID, Ramírez E, Díaz A, et al. Alteration of the sialylation pattern and memory deficits by injection of Aβ (25–35) into the hippocampus of rats. Neurosci Lett. 2011;495(1):11–16.
   PubMed Web of Science ®Google Scholar
• Ramos-Martinez I, Martínez-Loustalot P, Lozano L, et al. Neuroinflammation induced by amyloid β25-35 modifies mucin-type O-glycosylation in the rat’s hippocampus. Neuropeptides. 2018;67:56–62.
   PubMed Web of Science ®Google Scholar
• Cerliani JP, Blidner AG, Toscano MA, et al. Translating the “sugar code” into immune and vascular signal programs. Trends Biochem Sci. 2017;42(4):255–273.
   PubMed Web of Science ®Google Scholar
• Liu FT, Rabinovich GA. Galectins: regulators of acute and chronic inflammation. Ann N Y Acad Sci. 2010;1183:158–182.
   PubMed Web of Science ®Google Scholar
• Liu FT, Yang RY, Hsu DK. Galectins in acute and chronic inflammation. Ann N Y Acad Sci. 2012;1253:80–91.
   PubMed Web of Science ®Google Scholar
• Skovronsky DM, Lee VMY, Trojanowski JQ. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol Mech Dis. 2006;1:151–170.
   PubMed Web of Science ®Google Scholar
• Bachiller S, Jiménez-Ferrer I, Paulus A, et al. Microglia in neurological diseases: a road map to brain-disease dependent-inflammatory response. Front Cell Neurosci. 2018;18(12):488.
   Google Scholar
• Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol. 2017;35:441–468.
   PubMed Web of Science ®Google Scholar
• Fan H, Zhang K, Shan L, et al. Reactive astrocytes undergo M1 microglia/macrohpages-induced necroptosis in spinal cord injury. Mol Neurodegener. 2016;11:14.
   PubMed Web of Science ®Google Scholar
• Stratoulias V, Venero JL, Tremblay MÈ, et al. Microglial subtypes: diversity within the microglial community. Embo J. 2019;38(17):e101997.
   PubMed Web of Science ®Google Scholar
• Holtman IR, Skola D, Glass CK. Transcriptional control of microglia phenotypes in health and disease. J Clin Invest. 2017;127(9):3220–3229.
   PubMed Web of Science ®Google Scholar
• Shechter R, Schwartz M. Harnessing monocyte-derived macrophages to control central nervous system pathologies: no longer ‘if’ but ‘how’. J Pathol. 2013;229:332–346.
   PubMed Web of Science ®Google Scholar
• Chhor V, Le Charpentier T, Lebon S, et al. Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav Immun. 2013;32:70–85.
   PubMed Web of Science ®Google Scholar
• Singhal G, Jaehne EJ, Corrigan F, et al. Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front Neurosci. 2014;8:315.
   PubMed Web of Science ®Google Scholar
• Block ML, Zecca L, Houg JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8:57–69.
   PubMed Web of Science ®Google Scholar
• Sofroniew MV. Multiple roles for astrocytes as effector of cytokines and inflammatory mediators. Neuroscientist. 2014;20:160–172.
   PubMed Web of Science ®Google Scholar
• Davis AA, Leyns CEG, Holtzman DM. Intracellular spread of protein aggregates in neurodegenerative disease. Annu Rev Cell Dev Biol. 2018;34:3.1–3.24.
   PubMed Web of Science ®Google Scholar
• Cherry JD, Olschowka JA, O’Banio MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014;11:98.
   PubMed Web of Science ®Google Scholar
• Kirkley KS, Popichak KA, Afzali MF, et al. Microglia amplify inflammatory activation of astrocytes in manganese neurotoxicity. J Neuroinflammation. 2017;14:99.
   PubMed Web of Science ®Google Scholar
• Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14:463–477.
   PubMed Web of Science ®Google Scholar
• Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148(6):1204–1222.
   PubMed Web of Science ®Google Scholar
• Gasparotto J, Girardi CS, Somensi N, et al. Receptor for advanced glycation end products mediates sepsis-triggered amyloid-β accumulation, Tau phosphorylation, and cognitive impairment. J Biol Chem. 2018;293(1):226–244.
   PubMed Web of Science ®Google Scholar
• Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388–405.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ulland TK, Ulrich JD, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213(5):667–675.
   PubMed Web of Science ®Google Scholar
• Ulland TK, Song WM, Huang SC, et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s disease. Cell. 2017;170(4):649–663.
   PubMed Web of Science ®Google Scholar
• Carmona S, Zahs K, Wu E, et al. The role of TREM2 in Alzheimer’s disease and other neurodegenerative disorders. Lancet Neurol. 2018;17(8):721–730.
   PubMed Web of Science ®Google Scholar
• Wang Y, Cella M, Mallinson K, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell. 2015;160(6):1061–1071.
   PubMed Web of Science ®Google Scholar
• Krasemann S, Madore C, Cialic R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47(3):566–581.
   PubMed Web of Science ®Google Scholar
• Boza-Serrano A, Ruiz R, Sanchez-Varo R, et al., Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease. Acta Neuropathol. 2019;138(2):251–273.
   PubMed Web of Science ®Google Scholar
• Kinney JW, Bemiller SM, Murtishaw AS, et al. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimer’s Dement (N Y). 2018;4:575–590.
   PubMedGoogle Scholar
• Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358–372.
   PubMed Web of Science ®Google Scholar
• Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med. 2012;2(1):a006346.
   PubMed Web of Science ®Google Scholar
• Frost GR, Jonas LA, Li YM. Friend, foe or both? Immune activity in Alzheimer’s disease. Front Aging Neurosci. 2019;11:337.
   PubMed Web of Science ®Google Scholar
• Fahn S. Description of Parkinson’s disease as a clinical syndrome. Ann N Y Acad Sci. 2003;991:1–14.
   PubMed Web of Science ®Google Scholar
• Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896–912.
   PubMed Web of Science ®Google Scholar
• Caggiu E, Arru G, Hosseini S, et al. Inflammation, infectious triggers, and Parkinson’s disease. Front Neurol. 2019;10:122.
   PubMed Web of Science ®Google Scholar
• Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(1):S210–2.
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19.
   PubMed Web of Science ®Google Scholar
• Mosley RL, Hutter-Saunders JA, Stone DK, et al. Inflammation and adaptive immunity in Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2(1):a009381.
   PubMed Web of Science ®Google Scholar
• Boza-Serrano A, Reyes JF, Rey NL, et al. The role of galectin-3 in α-synuclein-induced microglia activation. Acta Neuropathol Commun. 2014;2:156.
   PubMed Web of Science ®Google Scholar
• Labbadia J, Morimoto RI. Huntington’s disease: underlying molecular mechanisms and emerging concepts. Trends Biochem Sci. 2013;38(8):378–385.
   PubMed Web of Science ®Google Scholar
• Möller T. Neuroinflammation in Huntington’s disease. J Neural Transm. 2010;117(8):1001–1008.
   PubMed Web of Science ®Google Scholar
• Rocha NP, Ribeiro FM, Furr-Stimming E, et al. Neuroimmunology of Huntington’s disease: revisiting evidence from human studies. Mediators Inflamm. 2016;2016:8653132.
   PubMed Web of Science ®Google Scholar
• Soulet D, Cicchetti F. The role of immunity in Huntington’s disease. Mol Psychiatry. 2011;16(9):889–902.
   PubMed Web of Science ®Google Scholar
• Campbell G, Mahad D. Neurodegeneration in progressive multiple sclerosis. Cold Spring Harb Perspect Med. 2018;8:10.
   Web of Science ®Google Scholar
• Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(5):1175–1189.
   PubMedGoogle Scholar
• Pérez-Cerdá F, Sánchez-Gómez MV, Matute C. The link of inflammation and neurodegeneration in progressive multiple sclerosis. Mult Scler Demyelinating Disord. 2016;1:9.
   Google Scholar
• Matthews PM. Chronic inflammation in multiple sclerosis - seeing what was always there. Nat Rev Neurol. 2019;15(10):582–593.
   PubMed Web of Science ®Google Scholar
• Bjelobaba I, Savic D, Lavrnja I. Multiple sclerosis and neuroinflammation: the overview of current and prospective therapies. Curr Pharm Des. 2017;23(5):693–730.
   PubMed Web of Science ®Google Scholar
• Cluskey S, Ramsden DB. Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. Mol Pathol. 2001;54(6):386–392.
   PubMedGoogle Scholar
• Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol. 2017;8:1005.
   PubMed Web of Science ®Google Scholar
• McCombe PA, Henderson RD. The role of immune and inflammatory mechanisms in ALS. Curr Mol Med. 2011;11(3):246–254.
   PubMed Web of Science ®Google Scholar
• Moisse K, Strong MJ. Innate immunity in amyotrophic lateral sclerosis. Biochim Biophys Acta. 2006;1762(11–12):1083–1093.
   PubMed Web of Science ®Google Scholar
• Rusconi M, Gerardi F, Santus W, et al. Inflammatory role of dendritic cells in amyotrophic lateral sclerosis revealed by an analysis of patients’ peripheral blood. Sci Rep. 2017;7(1):7853.
   PubMedGoogle Scholar
• Kriz J, Lalancette-Hébert M. Inflammation, plasticity and real-time imaging after cerebral ischemia. Acta Neuropathol. 2009;117(5):497–509.
   PubMed Web of Science ®Google Scholar
• Fang M, Zhong L, Jin X, et al. Effect of inflammation on the process of stroke rehabilitation and poststroke depression. Front Psychiatry. 2019;10:184.
   PubMed Web of Science ®Google Scholar
• Jayaraj RL, Azimullah S, Beiram R, et al. Neuroinflammation: friend and foe for ischemic stroke. J Neuroinflammation. 2019;16(1):142.
   PubMed Web of Science ®Google Scholar
• Lambertsen KL, Finsen B, Clausen BH. Post-stroke inflammation-target or tool for therapy? Acta Neuropathol. 2019;137(5):693–714.
   PubMed Web of Science ®Google Scholar
• Ramiro L, Simats A, García-Berrocoso T, et al. Inflammatory molecules might become both biomarkers and therapeutic targets for stroke management. Ther Adv Neurol Disord. 2018;11:1756286418789340.
   Web of Science ®Google Scholar
• Stoll G, Nieswandt B. Thrombo-inflammation in acute ischaemic stroke - implications for treatment. Nat Rev Neurol. 2019;15(8):473–481.
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Croci DO. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity. 2012;36:322–335.
   PubMed Web of Science ®Google Scholar
• Vasta GR, Ahmed H, Nita-Lazar M, et al. Galectin as self/non-self recognition receptors in innate and adaptive immunity: an unresolved paradox. Front Immunol. 2012;3:199.
   PubMed Web of Science ®Google Scholar
• Di Lella S, Sundblad V, Cerliani JP, et al. When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry. 2011;50:7842–7857.
   PubMed Web of Science ®Google Scholar
• Varki A. Biological roles of glycans. Glycobiology. 2017;27:3–49.
   PubMed Web of Science ®Google Scholar
• Alavi A, Axford JS. Sweet and sour: the impact of sugars on disease. Rheumatology. 2008;47:760–770.
   PubMed Web of Science ®Google Scholar
• Starossom SC, Mascanfroni ID, Imitola J, et al. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity. 2012;37:249–263.
   Google Scholar
• Burguillos MA, Svensson M, Schulte T, et al. Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation. Cell Rep. 2015;10:S2211-1247(15)00140-0.
   PubMed Web of Science ®Google Scholar
• Dhirapong A, Lleo A, Leung P, et al. The immunological potential of galectin-1 and −3. Autoimmun Rev. 2009;8:360–363.
   PubMed Web of Science ®Google Scholar
• Toscano MA, Campagna L, Molinero LL, et al. Nuclear factor (NF)-κB controls expression of the immunoregulatory glycan-binding protein galectin-1. Mol Immunol. 2011;48:1940–1949.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Hirabayashi J, Manya H, et al. Galectin-1 induces astrocyte differentiation, wich leads to production of brain-derived neutrophic factor. Glycobiology. 2004;14:357–363.
   PubMed Web of Science ®Google Scholar
• Sofroniew MV. Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci. 2015;16:249–263.
   PubMed Web of Science ®Google Scholar
• Sirko S, Irmler M, Gascón S, et al. Astrocyte reactivity after brain injury-: the role of galectins 1 and 3. Glia. 2015;63:2340–2361.
   PubMed Web of Science ®Google Scholar
• Camby I, Le Mercier M, Lefranc F, et al. Galectin-1: a small protein with major functions. Glycobiology. 2006;16:137R–157R.
   PubMed Web of Science ®Google Scholar
• Ishibashi S, Kuroiwa T, Sakaguchi M, et al. Galectin-1 regulates neurogenesis in the subventricular zone and promotes functional recovery after stroke. Exp Neurol. 2007;207(2):302–313.
   PubMed Web of Science ®Google Scholar
• Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760(4):616–635.
   PubMed Web of Science ®Google Scholar
• Yan YP, Lang BT, Vemuganti R, et al. Galectin-3 mediates post-ischemic tissue remodeling. Brain Res. 2009;1288:116–124.
   PubMed Web of Science ®Google Scholar
• Shin T. The pleiotropic effects of galectin-3 in neuroinflammation: a review. Acta Histochem. 2013;115:407–411.
   PubMed Web of Science ®Google Scholar
• Jeon SB, Yoon HJ, Chang CY, et al. Galectin-3 exerts cytokine regulatory actions through the JAK-STAT pathway. J Immunol. 2010;185:7037–7046.
   PubMed Web of Science ®Google Scholar
• Wesley UV, Vemuganti R, Ayvaci ER, et al. Galectin-3 enhanced angiogenic and migratory potential of microglia cells via modulation of integrin linked kinase signaling. Brain Res. 2013;1496:1–9.
   PubMed Web of Science ®Google Scholar
• Lalancette-Hébert M, Swarup V, Beaulieu JM, et al. Galectin-3 is required for resident microglia activation and proliferation in response to ischemic injury. J Neurosci. 2012;32:10383–10395.
   PubMed Web of Science ®Google Scholar
• Yang M, Kim J, Kim T, et al. Possible involvement of galectin-3 in microglial activation in the hippocampus with trimethyltin treatment. Neurochem Int. 2012;61:955–962.
   PubMed Web of Science ®Google Scholar
• Comte I, Kim Y, Young CC, et al. Galectin-3 maintains cell motility from the subventricular zone to the olfactory bulb. J Cell Sci. 2011;124:2438–2447.
   PubMed Web of Science ®Google Scholar
• Sakaguchi M, Imaizumi Y, Okano H. Expression and function of galectin-1 in adult neural stem cells. Cell Mol Life Sci. 2007;64:1254–1258.
   PubMed Web of Science ®Google Scholar
• Heilmann S, Hummel T, Margolis FL, et al. Immunohistochemical distribution of galectin-1, galectin-3, and olfactory marker in human olfactory epithelium. Histochem Cell Biol. 2000;113:241–245.
   PubMed Web of Science ®Google Scholar
• Qu WS, Wang YH, Ma JF, et al. Galectin-1 attenuates astrogliosis-associated injuries and improves recovery of rats following focal cerebral ischemia. J Neurochem. 2011;116:217–226.
   PubMed Web of Science ®Google Scholar
• Pasquini LA, Millet V, Hoyos HC, et al. Galectin-3 drives oligodendrocyte differentiation to control myelin integrity and function. Cell Death Differ. 2011;18:1746–1756.
   PubMed Web of Science ®Google Scholar
• Satoh K, Niwa M, Binh NH, et al. Increase of galectin-3 expression in microglia by hyperthermia in delayed neuronal death of hippocampal CA1 following transient forebrain ischemia. Neurosci Lett. 2011;540:199–203.
   Google Scholar
• Ramírez E, Sánchez-Maldonado C, Mayoral MA, et al. Neuroinflammation induced by the peptide amyloid-β (25-35) increase the presence of galectin-3 in astrocytes and microglia and impairs spatial memory. Neuropeptides. 2019;74:11–23.
   PubMed Web of Science ®Google Scholar
• Siew JJ, Chen HM, Chen HY, et al. Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington’s disease. Nat Commun. 2019 Aug 2;10(1):3473.
   PubMedGoogle Scholar
• Doverhag C, Hedtjärn M, Poirier F, et al. Galectin-3 contributes to neonatal hypoxic-ischemic brain injury. Neurobiol Dis. 2010;38:36–46.
   PubMed Web of Science ®Google Scholar
• Lerman BJ, Hoffman EP, Sutherland ML, et al. Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Brain Behav. 2012;2:563–575.
   PubMed Web of Science ®Google Scholar
• Jiang HR, Al Rasebi Z, Mensah-Brown E, et al. Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J Immunol. 2009;182:1167–1173.
   PubMedGoogle Scholar